Kynamro
Homozygous Familial Hypercholesterolemia
Treatment
2 FDA approvals
2 Active Studies for Kynamro
Treatment for
Homozygous Familial Hypercholesterolemia
What is Kynamro
Mipomersen
The Generic name of this drug
Treatment Summary
Mipomersen sodium, also known as Kynamro, is a drug used to treat homozygous familial hypercholesterolemia, a genetic disorder that causes high levels of cholesterol and other fats in the blood. Mipomersen works by blocking the formation of Apo B-100 and reducing levels of LDL cholesterol and total cholesterol. This drug carries a black box warning due to its potential to cause liver damage, so it is only available to patients under a special safety program called the Kynamro Risk Evaluation and Mitigation Strategy program.
Kynamro
is the brand name
Kynamro Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kynamro
Mipomersen
2013
3
Approved as Treatment by the FDA
Mipomersen, otherwise called Kynamro, is approved by the FDA for 2 uses which include Homozygous Familial Hypercholesterolemia and Homozygous Familial Hypercholesterolaemia (HoFH) .
Homozygous Familial Hypercholesterolemia
Helps manage Homozygous Familial Hypercholesterolaemia (HoFH)
Homozygous Familial Hypercholesterolaemia (HoFH)
Helps manage Homozygous Familial Hypercholesterolaemia (HoFH)
Effectiveness
How Kynamro Affects Patients
Mipomersen sodium helps to lower the amount of cholesterol and other fats in the blood, including apolipoprotein B, low density lipoprotein, and non-high density lipoprotein cholesterol.
How Kynamro works in the body
Mipomersen attaches to the instructions that tell the body to make apoB-100. This prevents the body from using those instructions, and so the protein is not made.
When to interrupt dosage
The amount of Kynamro depends on the diagnosed affliction. The quantity of dosage is contingent upon the technique of delivery delineated in the table below.
Condition
Dosage
Administration
Homozygous Familial Hypercholesterolemia
, 200.0 mg/mL
, Subcutaneous, Injection, solution - Subcutaneous, Injection, solution
Warnings
Kynamro has four contraindications and should not be utilized when encountering the conditions presented in the subsequent table.
Kynamro Contraindications
Condition
Risk Level
Notes
Liver Diseases
Do Not Combine
Moderate Hepatic Impairment
Do Not Combine
Transaminases
Do Not Combine
Severe Hepatic Impairment
Do Not Combine
There are 2 known major drug interactions with Kynamro.
Common Kynamro Drug Interactions
Drug Name
Risk Level
Description
Pexidartinib
Major
Mipomersen may increase the hepatotoxic activities of Pexidartinib.
Methotrexate
Moderate
Mipomersen may increase the hepatotoxic activities of Methotrexate.
Kynamro Toxicity & Overdose Risk
Mipomersem has a black box warning of potential liver damage. Other, less serious side effects include nausea, headache, fatigue, and pain or discomfort at the injection site. Some people may also experience similar symptoms to the flu.
Kynamro Novel Uses: Which Conditions Have a Clinical Trial Featuring Kynamro?
Five active studies are currently assessing the potential of Kynamro in treating Homozygous Familial Hypercholesterolemia.
Condition
Clinical Trials
Trial Phases
Homozygous Familial Hypercholesterolemia
2 Actively Recruiting
Phase 3
Kynamro Reviews: What are patients saying about Kynamro?
3
Patient Review
3/29/2013
Kynamro for Homozygous Inherited High Blood Cholesterol
Patient Q&A Section about kynamro
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How does mipomersen work?
"The drug mipomersen works by binding to a specific RNA sequence, which in turn prevents the production of a protein called apoB."
Answered by AI
When was Kynamro discontinued?
"As of August 2019, Kynamro (mipomersen) is no longer available in the United States. It is unclear why the FDA withdrew its approval for this medication."
Answered by AI
What is Kynamro used for?
"Kynamro can be used in addition to other cholesterol-lowering medications and a healthy diet to help reduce levels of low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."
Answered by AI
What is the mechanism of action of lomitapide?
"As a result, hepatic secretion of triglycerides, apolipoprotein B-100 and cholesterol are decreased.
The microsomal triglyceride transfer protein (MTP or MTTP) is necessary for very low-density lipoprotein (VLDL) assembly and secretion in the liver. Lomitapide decreases the MTP, which then decreases the hepatic secretion of triglycerides, apolipoprotein B-100 and cholesterol."
Answered by AI